摘要:

The authors treated 39 heavily pretreated breast cancer patients, median age 72, with a combined oral regimen featuring idarubicin and cyclophosphamide, administered without hospitalization in cycles repeated every 4 weeks for a total not to exceed idarubicin 400 mg/m2. Treatment was remarkably well tolerated, with generally mild hematological toxicity and only one discontinuation caused by severe neutropenia; non-hematologic toxicity consisted mainly of moderate nausea and vomiting in fewer than half the cycles, and hair loss of various severity in the majority of patients. Therapeutic results were graded as partial responses (13 cases), no change (NC; 11 cases) or progressive disease (11 cases) for a response rate of 37.2% (95% CI: 21.1–53.1%). The authors single out the NC issue as being of special interest, its mere occurrence being rewarding in the circumstance and its duration in excess of 5 months (seen in six cases) almost equivalent to therapeutic success.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Patients with colorectal carcinoma progressing after a 5-fluorouracil (5-FU)-containing regimen were eligible. One treatment cycle consisted of repeated administrations of 5-FU combined to folinic acid for six times and to oxaliplatin for three times over 50 days. 5-FU was given at the dose of 2.6 g/m2as a continuous infusion over 24 h on days 1, 8, 22, 29 and 43 preceded by i.v. folinic acid (FA) at a dose of 500 mg/m2over 1 h. Oxaliplatin was given 1 h after 5-FU at the dose of 130 mg/m2over a 2 h infusion on days 1, 22 and 43. A total of 37 patients were treated according to this schedule. The rates of objective responses after the first and second treatment cycles were 28 and 17%, respectively, with rates of tumor growth control, i.e. including the stabilizations, of 55 and 28%. The median duration of response was 10 months and the median duration of stabilizations was 6 months. The median survival time from initiation of oxaliplatin-containing therapy Is 10 months (2–28+). The median survival time from the diagnosis of metastatJc disease is 24 months (2–40+). The main toxicities were leucopenia, diarrhea, fatigue and paresthesias. The combination of 5-FU/FA/oxaliplatin was well tolerated and appears as a meaningful therapy after failure of a previous 5-FU-containing treatment.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxicity. Toxicity was mild: apart from alopecia, grade 3 toxicities were leukopenia and thrombocytopenia in six patients, and grade 2 neurotoxicity in seven patients. Eight patients (22.2%, 95% CI: 9–35%) achieved an objective response, with a median duration of 5 months. Median survival time for all patients was 8 months. In 16 of 36 patients (44%), treatment determined a significant relief of symptoms. Out-patient paclitaxel given over 3 h may be effective as salvage treatment in patients with advanced gastric cancer refractory to first line chemotherapy.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Subtractive suppressive hybridization (SSH) and mRNA differential display reverse transcription-polymerase chain reaction (DDRT-PCR) were compared for their ability to detect the expression of drug-resistance associated genes in a doxorubicin-resistant and -sensitive colon carcinoma cell line (LoVo H67P). The expression pattern of more than 9000 bands obtained by DDRT-PCR were identical in both cell lines by more than 95%. Of the remaining differentially expressed DDRT-PCR products, 21 cDNA fragments were further analyzed after cloning. A total of 210 clones were sequenced resulting in 40 different sequences of which only five were differentially expressed as revealed by Northern blot analysis. SSH, on the other hand, resulted in 30 different sequences of 37 clones analyzed. Thirteen of 30 sequences (43%) could be identified by databank analysis (excluding expressed sequence tags) in contrast to nine of 40 clones (23%) obtained by DDRT-PCR. Of the clones identified by SSH, 60% exhibited a differential expression comparing the doxorubicin-resistant and -sensitive cell line, respectively, as compared to only 13% of the DDRT-PCR derived clones. The application of SSH resulted in the identification of differentially expressed genes in three doxorubin-resistant cell lines (LoVo DxR, ARH D60 and KB-V1) as compared to the sensitive parental cell lines. A significant higher expression of S100P, a protein involved in calcium metabolism, as well as MAGE 3 (melanoma antigen gene) was found in the resistant cell lines using this methodology. The expression of CAPL, a second protein involved in calcium metabolism, was only moderately elevated in the doxorubicin-resistant cells. We found that subtractive suppressive hybridization proved to be a more rapid and reliable method for the detection of differentially expressed mRNAs in our system.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Electropermeabilization (EPN), also termed electroporation, is a physical method to overcome the barrier of the cell membrane by applying short and intense electric pulses. It is the basis for a new cancer treatment modality, electrochemotherapy, where uptake of chemotherapeutics is enhanced by EPN. Preclinical and clinical trials have shown that application of electric pulses in vivo is feasible and that electrochemotherapy is highly efficient. The aim of this study was to develop an improved method of screening drugs on electropermeabilized versus non-electropermeabilized cells. In this study we describe an easy protocol which gives high cell viability, good reproducibility and a high rate of cell permeabilization. Cell cytotoxicity is simply determined by the MTT assay. Cell death due to the EPN procedure was less than 4% and more than 90% of cells were permeabilized. For daunorubicin, doxorubicin, etoposide and paclitaxel, no effect of EPN was found. For carboplatin and cisplatin the effect of EPN was a factor 3 and 2.3, respectively, on the IC50(inhibitory concentration 50%). For bleomycin we found a dramatic effect of EPN of the magnitude of a factor 300 on the IC50. In conclusion, we have established a new, easy and reliable protocol to test new drugs for cytotoxicity with or without the limitations of the cell membrane. Our data support the role of bleomycin as the drug of choice for electrochemotherapy.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Bone morphogenetic protein-2 (BMP-2) is a differentiation factor for normal osteoblasts. BMP-2 is structurally related to transforming growth factor-β which inhibits cell proliferation and enhances apoptosis. A recent study has shown the presence of BMP-2 receptors on several cancer cell lines. In this study, we attempted to determine if recombinant human BMP-2 (rhBMP-2) can modulate the proliferation of human tumor colony-forming units taken from 113 patients. Tumor cells were cultured in soft agar and continuously exposed to three concentrations of rhBMP-2 (10,100 and 1000 ng/ml) for 14 days in the capillary cloning system. There were 65 evaluable specimens, including 17 breast cancers, 15 ovarian cancers, 14 non-small cell lung cancers and five prostate cancers. Importantly, rhBMP-2 did not stimulate the tumor cell proliferation. A significant inhibition (50% or less survival of tumor colony-forming units) was seen in 16 of 65 specimens (24.6%) at 1000 ng/ml, including five of 14 non-small cell lung cancers, five of 17 breast tumors and two of 15 ovarian tumors. A concentration-response relationship was observed (p< 0.001 by Mantel-extension test). The results of this study encourage further evaluation of the antiproliferative effects of rhBMP-2 against human cancers.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

We investigated whether murine peritoneal macrophages treated with cisplatin or interferon (IFN)-γ alone, or in combination, could undergo apoptosis, and whether this results either from the cytotoxic effect of the activating agents or indirectly in an autocrine manner by the cytotoxic molecules released by them upon activation. Our data suggest that cisplatin, which has been shown to induce apoptosis in a number of normal as well as tumor cell types, did not induce apoptosis in murine peritoneal macrophages nor was apoptosis caused by IFN-γ. However, combined treatment with cisplatin and IFN-γ induced apoptosis in macrophages as studied by percent DNA fragmentation assay, qualitative analysis of DNA on agarose gel electrophoresis, and morphological and nuclear alterations studied by phase contrast and fluorescence microscopy. The factor responsible for inducing apoptosis in macrophages was found to be a higher concentration of NO produced by them upon activation with cisplatin and IFN-γ. Macrophages treated with cisplatin or IFN-γ alone produced a low level of NO and did not undergo apoptosis. The inhibitor of NO synthase, L-NMMA, prevented apoptosis in macrophages treated with cisplatin and IFN-γ, suggesting the involvement of NO in the induction of apoptosis in macrophages. The role of NO in inducing apoptosis in macrophages was further confirmed by the observation that direct treatment with sodium nitroprusside, a NO donor, resulted in apoptosis in macrophages. We have also shown that NO-induced apoptosis in macrophages activated with cisplatin and IFN-γ requires activation of an endonuclease, as the endonuclease inhibitor, aurine tricarboxylic acid, prevented apoptosis in them.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Synergistic effects of active hexose correlated compound (AHCC) extracted from mushroom on the treatment with UFT against mammary adenocarcinoma, SST-2 cells, in congenially T cell-depressed spontaneously hypertensive rats (SHR) were observed. AHCC plus UFT had slight but significant effects on the growth of primary tumors. Pulmonary metastases were not inhibited by the treatment with AHCC plus UFT, whereas metastases to axillay lymph nodes (LN) were obviously inhibited. Combination of AHCC plus UFT showed similar synergistic anti-metastatic effects in SHR rats with accelerated pulmonary metastases following the surgical removal of the primary tumors.In vitrostudies demonstrated that AHCC plus UFT enhanced the NK cell activity in tumor-bearing rats, whereas UFT alone depressed the NK cell activity. AHCC plus UFT also enhanced the NO production and cytotoxicity of peritoneal macrophages. In addition, AHCC restored the suppressed mRNA expression of interleukin-1 a and tumor necrosis factor-α induced by the chemotherapy. Taken together, the combination of AHCC plus UFT brought about good therapeutic effects not only on primary tumor growth but also on reducing metastasis and these effects were mediated by host immunity which was restored or activated by AHCC. AHCC may be a good candidate for a biological response modifier.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Chronic oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil suppressed thymidylate syntetase (TS) gene expression followed by reduction of TS activity in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene. Addition of medroxyprogesterone acetate (MPA) to the anticancer drug caused an additional decrease in TS and thymidine kinase activities in the tumor growth and restoration of bone loss. These results suggest that the simultaneous adminstration of MPA and anticancer drugs causes increased inhibition of mammary tumor growth and also diminishes the bone loss.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID

摘要:

Patients with advanced ovarian carcinoma and an inadequate response to first-line platinum-based combination chemotherapy (CTX) have a very poor prognosis and effective salvage regimens are clearly needed. This phase I study was performed in order to determine the maximum tolerable dose (MTD) and dose-limiting toxicity (DLT) of the combination paclitaxel (P) and ifosfamide (IFO). After premedication, patients received P as a 3 h i.v. infusion on day 1; IFO was given as 1 h i.v. infusion with the standard dose of mesna i.v. on days 2–5, q day 22. The following dose levels (dl) were investigated: (mg/m2/day) dl1, P 135/IFO 1500; dl2, P 135/IFO 2000; dl3, P 175/IFO 2000; and dl4, P 175/IFO 1500. Eighteen patients with advanced ovarian cancer entered this trial. In eight patients treated with an IFO dose of 2000 mg/m2during dl2 and 3, two required treatment interruptions because of CNS toxicity CTC grade 3 and one patient experienced nephrotoxicity CTC grade 3, Therefore the MTD of IFO used in combination with P and given over 4 days is reached with 2000 mg/m2/day. In the fourth dl we escalated the P dose up to 175 mg/m2, reduced the IFO dose to 1500 mg/m2and treated an additonal five patients. No DLT occured at that dl. Objective responses were observed at all dls. The combination of P and IFO is feasable and active in pretreated advanced ovarian carcinoma. dl4 is the recommended dose for phase II trials.

ISSN:0959-4973    

出版商:OVID    

年代:1998

数据来源: OVID